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Abstract: Central Nervous System (CNS) involvement in multiple myeloma and/or multifocal
solitary plasmacytoma is rare. Although they are unique entities, multiple myeloma (MM) and
plasmacytoma represent a spectrum of plasma cell neoplastic diseases that can sometimes occur
concurrently. Plasmacytomas very often present as late-stage sequelae of MM. In this case report,
we report a 53-year-old female presenting with right abducens cranial nerve (CN) VI palsy as an
initial presentation secondary to lesion of the right clivus.
Keywords: multiple myeloma; plasmacytoma; abducens nerve palsy

1. Introduction
Central Nervous System (CNS) involvement in multiple myeloma (MM) is uncommon,
with an incidence of approximately 1% of all MM cases [1,2]. CNS involvement suggests the
presence of either advanced stage sequela of MM known as intracranial plasmacytomas (occurring
in up to 5% of patients) [3], or solitary plasmacytoma without evidence of systemic disease.
Intracranial plasmacytomas are more common in the base of the skull and theyoriginate from bone
or paranasal sinus soft tissue. Initial symptoms can manifest as isolated or multiple cranial nerve
(CN) deficits.
MM and intracranial plasmacytoma represent a spectrum of plasma cell neoplasm. MM typically
presents with bone pain secondary to lytic bone lesions, an increase in serum and/or urine monoclonal
protein concentration, hypercalcemia, anemia, persistent or recurrent infections, and/or acute renal
failure [4]. In contrast, solitary plasmacytomas are localized plasma cell tumors arising from soft tissue
(extramedullary plasmacytomas) or bones (solitary bone plasmacytomas) without evidence of systemic
MM disease [5,6]. While CNS involvement in MM is rare, it is sometimes the only clinical finding
initially present. It is important to recognize that plasmacytoma can be associated with MM and early
recognition will hasten intervention. Presented is a case of intracranial plasmacytoma associated with
MM in a patient who presented with abducens nerve (CN VI) palsy as the initial clinical manifestation
of the disease.
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2. Case Presentation
A 53-year-old female with a history of type 2 diabetes mellitus, hypertension, and hypothyroidism
presented with increasing diplopia and nausea for six days. The patient experienced an unintentional
weight loss of 10 pounds in the preceding two weeks. Physical exam revealed bony tenderness
localized to the ribs as well as a right CN VI palsy manifesting as impaired right eye abduction.
Remainder of the exam was unremarkable.
Hemogram with differential was remarkable for white count of 10,700 k/µL (3.7–10.3 k/µL),
with absolute neutrophil count of 7.5 k/µL (1.6–6.1 k/µL). Absolute lymphocyte count was within
normal limits (2.42 k/µL (1.6–6.1 k/µL)). Blood chemistry was remarkable for: serum Ca2+ of
15.8 mg/dL (8.9–10.2 mg/dL), ionized Ca2+ of 7.7 mg/dL (4.6–5.1 mg/dL), and glucose of 254 mg/dL
(90–120 mg/dL). Parathyroid hormone was <10 pg/mL (12–72 pg/mL) and parathyroid hormone
related peptide was 1.3 (normal). Urine analysis and urine protein electrophoresis was unremarkable
without evidence of Bence-Jones protein. The calculated protein gap between total protein (6.8 g/dL)
and serum globulin (2.8 g/dL) was 4.0 g/dL and the albumin/gamma globulin ratio was elevated at
2.4 (0.8–2.0).
Serum
protein
electrophoresis
revealed
faint
monoclonal
immunoglobulin.
Serum immune-quantification showed IgG 1150 mg/dL (720–1598 mg/dL), IgA 200 mg/dL
(75–400 mg/dL), and IgM 41 (35–225 mg/dL). Kappa light chain was 108.18 mg/L (3.30–19.4 mg/L),
lambda light chain 445.32 mg/L (5.71–26.30 mg/L), with a kappa/lambda free light chain ratio of 0.24
(0.26–1.65). Bone marrow biopsy results demonstrated hypercellular bone marrow involved by plasma
cell neoplasm (50–60% aberrant lambda restricted plasma cells). Fluorescence in situ hybridization
studies found evidence of CCND1/IGH gene fusion and gain of chromosome 1q. Flow cytometry of
bone marrow aspirate demonstrated a small population of aberrant lambda restricted plasma cells
positive for CD38, CD56, moderate CD45 and Lambda, and negative for CD19.
Computed tomography (CT) of the chest/abdomen revealed multiple osteolytic lesions in the
appendicular and axillary skeleton throughout the thoracolumbar vertebral bodies, and pelvic bones;
a healing non-displaced fifth anterior lateral rib fracture was present on the right. CT and magnetic
resonance imaging (MRI) of the head showed multiple bone lesions, with a well-defined lesion
measuring 12 × 15 mm within the right side of the clivus adjacent to Dorello’s canal (Figures 1 and 2).
Bone survey showed lytic lesions in the left proximal fibular diaphysis (Figure 3).
The patient’s hypercalcemia was treated with IV normal saline, calcitonin, and pamidronate.
Pain was controlled with acetaminophen and tramadol with oxycodone for breakthrough pain.
The patient was evaluated by the hematology-oncology service and received external beam
radiation therapy to the clivus, alleviating her CN VI palsy. Her disease was then managed with
cyclophosphamide, bortezomib, and dexamethasone (CyBorD) chemotherapy. With treatment her
symptoms resolved. Three months into therapy, her repeat laboratory testing demonstrated good
response to treatment. The lambda light chain had decreased to 13.1 mg/L (5.71–26.30 mg/L), with a
normal kappa/lambda free light chain ratio of 1.0 (0.26–1.65). Furthermore, a repeat bone marrow
biopsy was obtained, which showed no morphologic evidence of multiple myeloma.
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Figure 1. Axial CT head demonstrating lytic bone lesion (indicated by red triangle) within the right

Figure
1. Axial
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demonstrating
lytic likely
bone lesion (indicated
by red triangle)
within the right
side of
clivus
to Dorello’s canal
for the patient’s
6th nervewithin
palsy. the right
Figure
1. the
Axial
CT adjacent
head demonstrating
lytic boneaccounting
lesion (indicated
by red triangle)
side of the clivus adjacent to Dorello’s canal likely accounting for the patient’s 6th nerve palsy.
side of the clivus adjacent to Dorello’s canal likely accounting for the patient’s 6th nerve palsy.

Figure 2. Axial T2 FS repeat (left) and T2 (right) demonstrating a discrete lesion (indicated by red
triangle) in the same region as CT scan. Lesion is seen on the right clivus adjascent to Dorello’s canal
and is likely responsible for CN 6 palsy. Lesion suspicious for myeloma and metastases. However,
Figure
2. Axial T2 FS repeat (left) and T2 (right) demonstrating a discrete lesion (indicated by red
Figure
2. Axial
T2 FS
repeatand
(left)
and T2
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demonstrating
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given
the signal
intensity
restricted
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is also aa discrete
possibility.

triangle) in the same region as CT scan. Lesion is seen on the right clivus adjascent to Dorello’s canal
triangle) in the same region as CT scan. Lesion is seen on the right clivus adjascent to Dorello’s canal and
and is likely responsible for CN 6 palsy. Lesion suspicious for myeloma and metastases. However,
is likely responsible for CN 6 palsy. Lesion suspicious for myeloma and metastases. However, given
given the signal intensity and restricted diffusion lymphoma is also a possibility.
the signal intensity and restricted diffusion lymphoma is also a possibility.
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Figure 3. Bone survey demonstrated lytic lesions in the left proximal fibular diaphysis.

Figure 3. Bone survey demonstrated lytic lesions in the left proximal fibular diaphysis.
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MM and plasmacytoma are a spectrum of plasma cell neoplastic disease, with MM accounting
for
about
one percent of are
all a
cancers
in the
USA and
the seconddisease,
most common
MM and plasmacytoma
spectrum
of plasma
cellisneoplastic
with MMhematologic
accounting for
malignancy
after
lymphoma.
In
2016,
there
were
an
estimated
30,300
new
cases,
12,650malignancy
deaths, and after
about one percent of all cancers in the USA and is the second most common hematologic
an incidence of about 4–5 per 100,000 in the United States (US) [7]. Plasmacytoma constitutes less
lymphoma.
In 2016, there were an estimated 30,300 new cases, 12,650 deaths, and an incidence of about
than 1% of intracranial tumors and can occur intramedullary or extramedullary. It can occur as a
4–5 per 100,000 in the United States (US) [7]. Plasmacytoma constitutes less than 1% of intracranial tumors
primary or secondary malignancy to widespread MM and can be classified into three groups. (1)
and can occur intramedullary or extramedullary. It can occur as a primary or secondary malignancy
plasmacytoma arising from the skull base; (2) plasmacytoma involving brain parenchyma +/− skull
to widespread
MM
and “intracranial
can be classified
three groups.
(1) plasmacytomas
plasmacytoma involving
arising from
the skull
involvement
termed
tumorinto
syndromes”;
and, (3)
the orbit
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brain parenchyma
+/− skull
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“intraorbitalinvolving
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[8]. Although
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early“intracranial
recognition tumor
is
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and,
(3)
plasmacytomas
involving
the
orbit
termed
“intraorbital
tumor
syndromes”
vital in advanced MM disease as it is associated with increased morbidity and mortality when [8].
Although
plasmacytoma
diagnosis
is delayed. is rare, early recognition is vital in advanced MM disease as it is associated with
is believed
to result from
malignant
increasedMM
morbidity
and mortality
when
diagnosistransformation
is delayed. of post-germinal center plasma cells
producing
a monoclonal
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plasmacytoma of
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tumors of plasma
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identical cells
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to result
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transformation
center
to
that
seen
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[9].
Plasmacytomas
that
occur
in
the
brain
are
termed
intracranial
plasmacytoma,
producing a monoclonal immunoglobulin, while plasmacytoma are tumors of plasma cells identical
and can arise from: (1) the clivus bone, which forms the junction between the basilar occipital and
to that
seen in MM [9]. Plasmacytomas that occur in the brain are termed intracranial plasmacytoma,
the sphenoid bone, (2) petrous part of the temporal bone, (3) or an extension of a plasmacytoma
and can arise from: (1) the clivus bone, which forms the junction between the basilar occipital and the
tumor arising from the submucosa of the nasopharyngeal region [3,8,10]. Due to the rarity of
sphenoid bone, (2) petrous part of the temporal bone, (3) or an extension of a plasmacytoma tumor
plasmacytomas, it is important to consider other differential diagnoses that include
arising
from the submucosa
of the nasopharyngeal
region [3,8,10].
Due to
the rarity
plasmacytomas,
chondrosarcomas
and meningiomas,
and osteosarcomas
and Ewing’s
tumor
for a of
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to the
consider
differential
include chondrosarcomas and meningiomas,
arising from
clivus other
and petrous
bone, diagnoses
respectivelythat
[3,11].
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andof
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tumor fordepend
a plasmacytoma
arising
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The symptoms
a plasmacytoma
on the location
and from
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tumor.and
Patients
maybone,
respectively
[3,11].
present with
headache, seizures, focal neurologic deficits, or cranial nerve palsies [11]. Although any
cranial
nerve can of
be aaffected,
unilateraldepend
CN VI palsy
is alocation
common and
presentation
[8]. tumor.
This is due
to the may
The symptoms
plasmacytoma
on the
size of the
Patients
extended
course taken
by CN VI
between
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and theorclivus
to pierce
dura[11].
mater
between any
present
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seizures,
focal
neurologic
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cranial
nerve the
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Although
thenerve
dura and
To achieve
this, CN
VIVI
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pass
Dorello’s
canal and bend
theispetrous
cranial
can skull.
be affected,
unilateral
CN
palsy
is avia
common
presentation
[8]. at
This
due to the
temporal bone, traveling into the superior orbital fissure to innervate the lateral rectus muscle of the
extended course taken by CN VI between the pons and the clivus to pierce the dura mater between
eye. Patients with CN VI deficits will present with diplopia due to the inability to abduct the affected
the dura and skull. To achieve this, CN VI fibers pass via Dorello’s canal and bend at the petrous
eye. Other nerves commonly affected include CN II and III [12].

temporal bone, traveling into the superior orbital fissure to innervate the lateral rectus muscle of the
eye. Patients with CN VI deficits will present with diplopia due to the inability to abduct the affected
eye. Other nerves commonly affected include CN II and III [12].
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As previously mentioned, a plasmacytoma can be solitary or secondary to MM. Diagnosis of a
solitary plasmacytoma depends on positive biopsy-proven clonal plasma cells solitary lesion without
any evidence of systemic MM disease. Diagnosis is confirmed with lytic homogenous, soft-tissue
density on CT or MRI. MRI is favored over CT for tumor imaging and it will show isointense focus [13].
Plasmacytomas can also arise in the context of MM [14].
Molecular characterization of MM can provide useful clinical information regarding prognosis and
therapy stratification. The presence of specific cytogenetic high-risk abnormalities, including t(4;14),
t(14;16), t(14;20), del(17p), and dup(1q) were previously identified to confer a poor prognosis [15–17].
On cytogenetic analysis, our patient was found to have CCND1/IGH gene fusion, which is commonly
known as t(11;14) fusion and dup(1q). It should be noted that t(11:14) is a neutral or favorable
prognostic factor in MM; however, in patients with light chain amyloidosis it confers a hazard ratio
for death of 2.5 [18]. Duplications of 1q are considered secondary genetic abnormalities in MM and
are typically associated with disease progression, high-risk disease, and shorter survival [17]. This is
likely secondary to the fact that duplications of 1q reflect an increase in the gene dosage of proliferative
genes, like CKS1B [16,17,19].
Clinically, it is difficult to ascertain whether a plasmacytoma is a clinical sequela of MM or if
the plasmacytoma progressed to MM. Nevertheless, both circumstances carry a worse prognosis
and should be aggressively treated. Treatment consists of localized radiotherapy for plasmacytoma
along with systemic chemotherapy for concurrent MM. The choice of chemotherapy regimen depends
on MM risk stratification; combination chemotherapy regimen, such as bortezomib, lenalidomide,
and low dose dexamethasone are often recommended initial agents for treatment [20].
4. Conclusions
CNS involvement in MM is rare. It commonly manifests as an intracranial plasmacytoma and
it typically indicates late stage MM with poor prognosis. The initial clinical presentation includes
diplopia, bone pain, and weight loss. Although a solitary plasmacytoma can manifest without MM
co-morbidity, it can progress to MM [11]. Thus, prompt recognition and treatment of the plasmacytoma
is warranted.
Our patient’s chief complaint was diplopia, with clinical findings of hypercalcemia and a clivus
bone lytic lesion being discovered on workup. Therefore, it is important to consider conducting an
MM workup in any patient presenting with diplopia and an accompanying lytic bone lesion found
on imaging.
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